JP2007509055A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509055A5 JP2007509055A5 JP2006535354A JP2006535354A JP2007509055A5 JP 2007509055 A5 JP2007509055 A5 JP 2007509055A5 JP 2006535354 A JP2006535354 A JP 2006535354A JP 2006535354 A JP2006535354 A JP 2006535354A JP 2007509055 A5 JP2007509055 A5 JP 2007509055A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- immediate release
- group
- pharmaceutical composition
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51156003P | 2003-10-15 | 2003-10-15 | |
| US10/961,871 US20050142192A1 (en) | 2003-10-15 | 2004-10-08 | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
| PCT/US2004/034113 WO2005037287A1 (en) | 2003-10-15 | 2004-10-14 | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) en-2-yl)alkyl]phosphonic acid and derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509055A JP2007509055A (ja) | 2007-04-12 |
| JP2007509055A5 true JP2007509055A5 (enExample) | 2007-12-06 |
Family
ID=34704145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535354A Pending JP2007509055A (ja) | 2003-10-15 | 2004-10-14 | ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の経口投与 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050142192A1 (enExample) |
| EP (1) | EP1682151A1 (enExample) |
| JP (1) | JP2007509055A (enExample) |
| KR (1) | KR20070029114A (enExample) |
| AU (1) | AU2004281806A1 (enExample) |
| BR (1) | BRPI0415432A (enExample) |
| CA (1) | CA2541402A1 (enExample) |
| CO (1) | CO5690561A2 (enExample) |
| MX (1) | MXPA06003982A (enExample) |
| PA (1) | PA8614901A1 (enExample) |
| PE (1) | PE20050480A1 (enExample) |
| TW (1) | TW200528113A (enExample) |
| WO (1) | WO2005037287A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522834A (ja) * | 2003-04-09 | 2006-10-05 | ワイス | ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の鼻腔内投与用医薬組成物およびその使用法 |
| DE602004029146D1 (de) * | 2003-04-09 | 2010-10-28 | Wyeth Llc | Derivate von 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkylphosphonsäure und deren verwendung als n-methyl-d-aspartat- (nmda-) rezeptorantagonisten |
| TW200514775A (en) * | 2003-10-22 | 2005-05-01 | Wyeth Corp | Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof |
| US20050244365A1 (en) * | 2004-05-03 | 2005-11-03 | Novaflux Biosciences, Inc. | Methods, compositions, formulations, and uses of cellulose and acrylic-based polymers |
| RU2405566C9 (ru) | 2005-02-03 | 2012-04-27 | Дзе Дженерал Хоспитал Корпорейшн | Способ лечения рака, устойчивого к гефитинибу |
| PE20070763A1 (es) | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
| CA2697739A1 (en) * | 2007-08-27 | 2009-03-05 | Wyeth Llc | Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CA2714524A1 (en) * | 2008-02-11 | 2009-08-20 | Makiko Yanagida | Tablet having improved elution properties |
| DK2310011T3 (da) | 2008-06-17 | 2013-10-14 | Wyeth Llc | Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin |
| SG10202102855RA (en) | 2008-08-04 | 2021-05-28 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| US8778398B2 (en) * | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| US8771735B2 (en) * | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
| JP5992325B2 (ja) | 2009-04-06 | 2016-09-14 | ワイス・エルエルシー | 乳癌のための、ネラチニブを活用する治療計画 |
| CN102724962B (zh) | 2009-11-09 | 2017-05-17 | 惠氏有限责任公司 | 包衣药物球状体及其用于消除或减少病症比如呕吐和腹泻的用途 |
| DK4066821T3 (da) * | 2009-11-09 | 2025-04-14 | Wyeth Llc | Tabletformuleringer af neratinibmaleat |
| MX391660B (es) | 2010-03-24 | 2025-03-21 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas |
| RS67266B1 (sr) * | 2013-03-13 | 2025-10-31 | Sage Therapeutics Inc | Neuroaktivni steroidi i postupci za njihovu upotrebu |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| BR112018000129B1 (pt) | 2015-07-06 | 2024-01-09 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| SI3436022T1 (sl) | 2016-04-01 | 2022-08-31 | Sage Therapeutics, Inc. | Oksisteroli in postopki za uporabo le-teh |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| BR112021006027A2 (pt) | 2018-11-19 | 2021-06-29 | Jazz Pharmaceuticals Ireland Limited | formulações de fármaco resistente a álcool |
| AU2020231916B2 (en) | 2019-03-01 | 2025-08-28 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168103A (en) * | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
| US5124319A (en) * | 1991-10-11 | 1992-06-23 | American Home Products Corporation | Benzimidazole phosphono-amino acids |
| US5990307A (en) * | 1997-08-01 | 1999-11-23 | American Home Products Corporation | Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid |
| US6225343B1 (en) * | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
| US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| US20020160043A1 (en) * | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
| UA78529C2 (en) * | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
| JP4452970B2 (ja) * | 2002-03-27 | 2010-04-21 | 日本臓器製薬株式会社 | ジクロフェナクナトリウム経口製剤 |
| US20040082543A1 (en) * | 2002-10-29 | 2004-04-29 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| JP2006522834A (ja) * | 2003-04-09 | 2006-10-05 | ワイス | ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の鼻腔内投与用医薬組成物およびその使用法 |
-
2004
- 2004-10-08 US US10/961,871 patent/US20050142192A1/en not_active Abandoned
- 2004-10-13 TW TW093131004A patent/TW200528113A/zh unknown
- 2004-10-14 WO PCT/US2004/034113 patent/WO2005037287A1/en not_active Ceased
- 2004-10-14 MX MXPA06003982A patent/MXPA06003982A/es unknown
- 2004-10-14 KR KR1020067007283A patent/KR20070029114A/ko not_active Withdrawn
- 2004-10-14 EP EP04795300A patent/EP1682151A1/en not_active Withdrawn
- 2004-10-14 BR BRPI0415432-0A patent/BRPI0415432A/pt not_active IP Right Cessation
- 2004-10-14 AU AU2004281806A patent/AU2004281806A1/en not_active Abandoned
- 2004-10-14 JP JP2006535354A patent/JP2007509055A/ja active Pending
- 2004-10-14 CA CA002541402A patent/CA2541402A1/en not_active Abandoned
- 2004-10-14 PA PA20048614901A patent/PA8614901A1/es unknown
- 2004-10-15 PE PE2004001002A patent/PE20050480A1/es not_active Application Discontinuation
-
2006
- 2006-04-19 CO CO06037154A patent/CO5690561A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509055A5 (enExample) | ||
| CN1188422C (zh) | 钙(3s)四氢－3－呋喃基(1s,2r)－3－[[(4－氨基苯基)磺酰基](异丁基)氨基]－1－苯甲基－2－(膦酰氧基]丙基氨基甲酸酯 | |
| US11013722B2 (en) | Therapeutic agent for dyslipidemia | |
| CA2541402A1 (en) | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) en-2-yl)alkyl]phosphonic acid and derivatives | |
| JP2002500220A (ja) | 低脂血症性ベンゾチアゼピン化合物 | |
| WO2012071517A2 (en) | Novel crystalline forms | |
| CN1703204A (zh) | 含有碱性赋形剂的稳定的药物组合物 | |
| JP2012526094A5 (enExample) | ||
| JP2011529468A5 (enExample) | ||
| JP2002537258A5 (enExample) | ||
| CN1131669A (zh) | 光学活性苯并硫杂庚英衍生物，其制备方法和用途 | |
| CN1159305C (zh) | 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物 | |
| JP2006516643A5 (enExample) | ||
| JP2011513471A5 (enExample) | ||
| CN109803657B (zh) | 药物组合物 | |
| EP2943474B1 (en) | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors | |
| EA014383B1 (ru) | Гидрохлорид аморфного лерканидипина | |
| WO2004093875A1 (en) | Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these | |
| HUE028159T2 (en) | Acid addition salts of risperidone and pharmaceutical compositions containing them | |
| KR20200083545A (ko) | 치환된 페닐 설폰일 페닐 트리아졸 싸이온 및 이의 용도 | |
| WO2010048592A1 (en) | Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof | |
| CN1111407C (zh) | 抗癌组合物 | |
| SG185474A1 (en) | Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof | |
| WO2010054565A1 (zh) | 水溶性(r)-(-)-比卡鲁胺前药、其制备方法及用途 | |
| WO2020171507A1 (ko) | 모노메틸 푸마레이트 유도체 및 이들의 약학적 조성물 |